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Summary During the course of colon-rectum tumours a number of clinical events may occur in which
conventional cytopathology can provide only a partial contribution to the definition of a differential diagnosis,
i.e. effusions, distant recurrences and second neoplasias. In the present study we have evaluated whether
monoclonal antibody (MoAb) D612, recognising a colon-rectum associated antigen, can be used in this
context. To this end, MoAb D612 was employed in combination with a panel of MoAb of well defined
tumour specificity in immunocytochemical tests. The immunocytochemical findings obtained were compared
with the histological and clinical diagnosis. Of 62 effusions and 40 fine needle aspirates studied, MoAb D612
reactivity correlated with the correct diagnosis in 92.8% of the instances. These results indicate that this
reagent may help to improve the current cytopathological diagnosis of colon-rectum tumours by identifying
the colonic origin of metastases in patients with unknown primary tumour, differentiating ovarian carcinoma
from colon metastases to the ovaries and establishing the presence of a second neoplasia in patients with a
previous history other than colon carcinoma.
The increasing availability of monoclonal antibodies to
tumour associated antigens (TAA) has led to their use as an
adjunct in cytodiagnosis of solid tumours (Ghosh et al.,
1983; Johnston et al., 1985; Martin et al., 1988). This has
already resulted in a significant improvement of the diagnosis
of serous effusions occurring in patients with unknown
primary cancer (Mottolese et al., 1988).
The diagnosis of metastatic colon-rectum carcinoma relies
at present on a multidisciplinary approach. This includes the
evaluation of changes in the serum levels of tumour
associated markers (Mitchell, 1987), computed tomography
(CT) and echoscans which may be complemented by
cytological and more recently by immunocytochemical
methods (Bernardino, 1987) using monoclonal antibodies.
Despite this complementation a number of clinical situations,
i.e. effusions in patients with cryptic primary tumour, distinc-
tion between recurrence and second neoplasia, still remain
elusive to a correct diagnosis either because of difficulties in
cytological identification of tumour origin or because of the
lack of highly tumour specific MoAb. In the present study we
have evaluated whether the use of the novel MoAb D612
recognising a differentiation antigen of the intestinal tract
(Muraro et al., 1989) in immunocytochemical assays can aid
as an adjunct to the cytological diagnosis of colon-rectum
cancer. Results to be presented demonstrate that, when used
in combination with a panel of selected MoAb, this reagent
may help to identify: (a) the colonic origin of metastases in
patients with occult primary colon rectum cancer; (b) colon-
rectum metastases to the ovary; and (c) a second neoplasia in




One hundred and two patients evaluated in this study were
admitted to the Regina Elena Cancer Institute. For the aim
of the present investigation they were stratified in two main
groups as follows. Group A included 12 patients bearing
metastatic effusions and 16 patients with single or multiple
pulmonary and/or abdominal masses which appeared during
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the clinical course following the removal of a colon-rectum
cancer. Group B included 50 patients with either a pleural or
a peritoneal effusion of unknown origin and 24 patients
affected by single or multiple pulmonary or abdominal
masses with no past history of neoplasia.
Sampling ofeffusions andpreparation ofcell substrates
Pleural and peritoneal effusions were collected in sterile con-
ditions using heparin (Liquemin, Roche) as anticoagulant.
Cells were separated by centrifugation at 160g for 10min,
washed three times with Hanks' balanced salt solution
(HBSS) (Gibco Lab., Paisley, UK) and resuspended in the
same medium at a density of 1 x 106 cellsml-'. When the
effusions were highly contaminated by red blood cells, ery-
throcytes were removed by lysis with TRIS-HN4CI pH 7.4 for
10min at 37°C. Cytospins were obtained using a Shandon
cytocentrifuge (Shandon, Runcorn, Cheshire, UK) and used
for conventional morphological diagnosis after staining with
the Papanicolau and May-Grunwald methods or fixed for
10min in absolute acetone for immunocytochemical evalua-
tion. After fixation cytospins were either immediately pro-
cessed or stored at - 20°C for at least 4 months with no loss
of immunological reactivity.
Fine needle aspiration biopsy: procedure andsampling ofcell
substrates
Fine needle aspiration biopsies were performed under local
anesthaesia using a 22 gauge needle placed on a 20 ml dis-
posable syringe mounted on a special holder (Cameco 20 ml,
Precision Dynamics, Burbank, CA, USA). Lesions of sizes
ranging from 1 to 5 cm in diameter were successfully
aspirated. The correct needle insertion was assessed by a grid
placed on the patient's skin and subsequently the proper
needle placement was verified by CT scan. Cellular speci-
mens were immediately smeared onto acid clean glass slides
and fixed in 95% ethanol for conventional Papanicolau stain-
ing or fixed for 10 min in cold absolute acetone for
immunocytochemical evaluation.
Monoclonal andpolyclonal antisera
The murine MoAb D612 of the IgG2a isotype to a colorectal
specific antigen was produced by using as fusion partner of
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the non-secreting myeloma murine cell line P3-NSI-Ag4-1
splenocytes of Balb/c mice immunised with a membrane
enriched fraction of a moderately differentiated primary
colon carcinoma (Muraro et al., 1989). Other MoAbs (MBrl
(Canevari et al., 1983), OC-125 (Bast et al., 1981; Nouwen et
al., 1986), MOvl9 (Miotti et al., 1987) and KS1/4 (Varky et
al., 1984)) to various TAA used in this study were obtained
from different investigators or obtained commercially (B72.3
(Thor et al., 1986) and B6.2 (Colcher et al., 1981) (Sorin
Biomedica Saluggia VC Italy) (Table I) and were used either
as purified antibodies (Russo et al., 1983) or as culture
supernatants. Their use in diagnostic cytopathology has been
extensively described elsewhere (Szpack et al., 1984; Menard
et al., 1985; Mottolese et al., 1988). Fluorescein labelled
F(ab)2 fraction of a goat anti-mouse immunoglobulin
antiserum was obtained from Sorin Biomedica. Before its use
on tissue substrates the antiserum was extensively absorbed
with human ABRh+ red blood cells and with insolubilised
pooled normal human plasma (Avrameas & Ternynck, 1969).
The antiserum was employed at a protein concentration of
5001agmlm' with a fluorescein to protein ratio of 3.
Indirect immunofluorescence and immunoperoxidase
Indirect immunofluorescence (IIF) on acetone fixed speci-
mens were performed as follows. Cytospins were incubated
over night with MoAb to various TAA at 4°C. The protein
concentration of primary antibody ranged from 25 to
50 1gml-' in HBSS containing 1% bovine serum albumin
(BSA) (Sigma, St Louis, MO, USA). After three washes with
phosphate (0.01 M) buffered saline (0.15 M), pH 7.2 (PBS),
the specimens were incubated for 30 min at room
temperature with fluorescein labelled F(ab)2 goat anti-mouse
immunoglobulins antiserum. Following three washes with
cold PBS, cytospins and/or frozen sections were mounted.
with 50% buffered glycerol, pH 7.2, and examined under a
Leitz Orthoplan Microscope equipped with epillumination
and phase contrast observation. Control slides were prepared
by substituting the incubation with primary antibody with
HBSS plus 1% BSA.
Cell smears sampled by CT-FNA of pulmonary or
abdominal masses were fixed for 10 min in absolute acetone
and stained using an indirect avidin-biotin complex (ABC)
immunoperoxidase method with commercially available
reagents (Immucolor, Sorin Biomedica Saluggia VC, Italy)
(Hsu et al., 1981). Slides were incubated overnight with
MoAb to various TAA at 4°C in a moist chamber. The
enzymatic activity was developed using 3-amino-9-ethyl-
carbazole (AEC) as chromogenic substrate for 8 min at R/T.
Slides were then rinsed with PBS and counterstained with
Mayer's haematoxylin.
Immunoperoxidase stain for CT-FNA substrates was
chosen because of the possibility of analysing the cell
immunoreactivity in the context of the cellular morphology.
Results
Serologicalfeatures ofthe MoAb D612 recognising an
intestinal differentiation antigen
Following extensive immunohistochemical testing (Muraro et
al., 1989) MoAb D612 appeared valuable to be tested as an
adjunct to diagnostic immunocytology of colon-rectum
tumours. The high molecular weight antigen recognised by
MoAb D612 is restricted in fact in its distribution to the
intestinal epithelium. Of interest to this study the reagent
does not have any detectable reactivity with mesothelial cells.
Futhermore the antigen is expressed in about 85% of
primary colon-rectum carcinomas tested independently of
their degree of differentiation and in about 70% of hepatic
metastatic lesions. Only a minority of few other primary non
colon-rectum tumours displayed such heterogenous reactivity
with MoAb D612. This includes about 20% of mucinous
tumours from the ovary, and 20% of lung, breast and gastric
carcinomas. This range of distribution of reactivity of MoAb
D612 has been described in detail previously (Muraro et al.,
1989).
MoAb D612 identifies recurrences ofcolon-rectum tumours
The first part of this study was aimed at determining whether
the use of MoAb D612 on different cytological substrates,
which included cells harvested from effusions or collected by
FNA, could be useful in helping to reach an immuno-
cytochemical diagnosis of colon cancer. To this end cell
preparations from 28 patients who had undergone surgery
for colon-rectum tumours (disease-free interval ranging from
1 to 6 years) were assayed for the expression of a number of
TAA recognised by the panel of MoAb which has already
been shown (Mottolese et al., 1988) to help in increasing the
diagnostic accuracy of conventional cytopathology of other
neoplastic diseases.
As shown in Table II the immunoreactivity of MoAb
D612 and the anti-pancarcinoma MoAb B72.3 on various
cell preparations indicated an immunocytochemical correla-
tion in about 92.8% of the instances as confirmed by the
histopathological diagnosis, which reported 27 cases of
metastatic colon-rectum tumours and a primary lung neo-
plasia.
Only in one case did the reactivity of the lesion with
MoAb D612 and B72.3 and the lack of expression of the
other TAA suggest the wrong diagnosis of metastatic colon
carcinoma which was diagnosed by conventional histo-
pathology as primary lung carcinoma. As reported in the
footnote to Table II, testing MoAb D612 in separate control
experiments with similar cellular substrates sampled by
metastatic tumours of known histotypes such as breast, lung,
ovary gave negative findings in 95% of cases.
MoAb D612 helps to identify the originfrom colon-rectum of
metastatic effusions and non-palpable masses in patients with
occult primary cancer
MoAb D612 was employed on cell preparations obtained
from patients who presented with either effusions or deep
tumours of unknown origin. Also in this instance it helps to
reach a differential diagnosis when employed in combination
with a panel of other MoAb.
As shown in Table III the cell immunoreactivity of 50
effusions studied the cell immunoreactivity correlated with a
correct diagnosis of metastatic colon-rectum in six instances,
and in 17 cases of ovarian tumours (Figure la). The
immunocytochemical diagnosis failed in two cases of meta-
static lung carcinoma and two cases of breast carcinoma. The
immunodiagnostic performance of MoAb D612 on 24 FNA
Table I Monoclonal antibodies used for the immunocytochemical analysis
Molecular Major reactive
Antibody, Isotype Antigen weight (Da) tumour References
B72.3 IgGI Glycopr. 106 Adenocarcinomas Thor et al. (1986)
B6.2 IgGI Glycopr. 9 X 1O4 Breast ca. Colcher et al. (1981)
MBrI IgM Glycolip. Breast ca. Canevari et al. (1983)
OC-125 IgGi Glycopr. 0.5 x 106 Ovarian ca. Bast et al. (1981)
MOvl9 IgG2a Glycopr. 3.8 x 104 Ovarian ca. Miotti et al. (1987)
KSI/4 IgG2a Glycopr. 4 x 104 Lung ca. Varky et al. (1984)
D612 IgG2a Glycopr. 106 Colon ca. Muraro et al. (1989)628 M. MOTTOLESE et al.
Table II Immunocytochemical diagnosis of local recurrences and distant metastases in patients previously treated for a colon carcinoma
employing MoAb D612
Immunocytochemical Histopathological
Number of patients Site of lesion Reactivity with MoAb3 diagnosis diagnosis
8 Perit. effusion D612+ B72.3+ Metastatic colon ca. 7/8b
4 Pleur. effusion D612+ B72.3+ Metastatic colon ca. 4/4
11 Lungd D612+ B72.3+ Metastatic colon ca. 10/1IC
2 Liverd D612+ B72.3+ Metastatic colon ca. 2/2
2 Retroperitoneum D612+ B72.3+ Metastatic colon ca. 2/2
I Lungd D612- B72.3+ KSI/4+ OC-125+ Primary lung ca. 1/1
Total 28 26/28 (92.8%)
MoAb D612, tested on 20 breast, 25 ovarian and 15 lung carcinomas, was negative in 95% of the instances. aLack of reactivity with other
MoAb of the panel is not reported; bNo. confirmed diagnoses/no. tested; COne case D612+ was histopathologically diagnosed as primary lung
carcinoma; dSampled by CT-FNA.
Table III Immunocytochemical identification of the colonic origin of effusions of unknown origin employing
MoAb D612
Immunocytochemical Histopathological
Number of patients Reactivity with MoAba diagnosis diagnosis
6 D612+ B72.3+ Metastatic colon ca. 6/6"
17 B72.3+ MOvl9+ OC-125+ D612- Metastatic ovarian ca. 17/17
13 B72.3+ MBrl+ B6.2+ D612- Metastatic breast ca. 11/13C
10 B72.3+ KSI/4+ OC-125+ D612- Metastatic lung ca. 8/1od
4 B72.3+ D612 Undefined ca. 2 met. lung ca.
Total 50 2 met. breast ca.
aLack of reactivity with other MoAb of the panel is not reported; bNo. confirmed diagnoses/no. tested; C2 cases were
histopathologically diagnosed as metastatic lung carcinomas; d2 cases were histopathologically diagnosed as metastatic
ovarian carcinoma.
of tumour masses of undefined nature is reported in Table IV
and Figure lb. Indication of metastatic colon carcinoma can
be obtained in FNA of two pulmonary, three hepatic, one
retroperitoneal and two ovarian tumours by the combined
positive reactivity of MoAb D612 and B72.3.
Case reports
Two clinical cases in which the use of MoAb D612 on
cytologic specimens helped as an adjunct to provide a diag-
nosis are reported.
Patient S.M. was a 70-year-old male presented with a
single pulmonry mass 10 years following a laryngectomy for
an epidermoidal carcinoma, raising the question of whether
the lesion represented a recurrence, a metastasis from a
second neoplasia or a primary lung tumour. Conventional
cytological analysis performed on a CT-FNA of the mass
Ai
revealed an undifferentiated carcinoma. Immunocytochemical
analysis of the same cellular specimen employing our panel
of MoAb including MoAb D612 gave the following pattern _AF
of reactivity: B72.3', D612', KSI/4, OC-125-, which sug-
gested a metastatic colon carcinoma. The coloscopy, which
was then performed, demonstrated a papillary tumour of
5 mm diameter in the sigma which was diagnosed histo-
pathologically as an adenocarcinoma.
Patient S.L. was a 37-year-old female with no past history
of malignancy who presented at a pelvic CT scan with a AL
single adnexial mass infiltrating the intestinal mucosa. To
establish whether the lesion was primary or metastatic the
patient was submitted to ovarian FNA under CT guidance.
While conventional cytology demonstrated the presence of
malignant cells of undefined nature the immunocytochemical
analysis with the panel of monoclonal antibodies displayed a Figure 1 Avidin-biotin indirect immunoperoxidase assay using
homogeneous reactivity of the cells with MoAb D612 and MoAb D612 on cells harvested from a peritoneal effusion (a) and
B72.3 and no detectable reactivity with the other reagents, on cells sampled by fine needle aspiration of a single pulmonary
thus suggesting a diagnosis of intestinal adenocarcinoma mass (b). The immunoenzymatic reaction using 3-amino-9-ethyl-
metastatic to the ovary. Histopathological studies, subse- carbazole as substrate clearly outlines the cells of both specimens
quently performed, confirmed the immunocytochemical diag- indicating their metastatic origin from colon-rectum carcinomas
nosis. (a x 500; b x 160)
pelvis is not infrequently the first evidence of this malignancy
Discussion in a significant percentage of patients. Furthermore, while the
risk of local recurrence and/or distant metastases after
Clinical manifestations of colon carcinoma are often delayed 'curative surgery' is high, the symptoms of the recurrences
and a disseminated disease to the peritoneum or outside the are often aspecific and contribute minimally to diagnosis.IMMUNOCYTODIAGNOSIS OF COLON TUMOURS 629
Table IV Immunocytochemical identification of the colonic origin of deeply located masses of unknown nature employing MoAb D612
on FNA
Immunocytochemical Histopathological
Number of patients Site of lesionsA Reactivity with MoAba diagnosis diagnosis
2 Lung D612+ B72.3+ Metastatic colon ca. 2/2b
3 Liver D612+ B72.3+ Metastatic colon ca. 3/3
I Retroperitoneum D612+ B72.3+ Metastatic colon ca. 1/1
2 Ovary D612+ B72.3+ Metastatic colon ca. 2/2
3 Liver D612- B72.3+ Metastatic ovarian ca. 3/3
MOvl9+ OC-125+
10 Lung D612- B72.3+ KS1/4+ OC-125+ Primary lung ca. 10/10
2 Lung D612- B72.3+ Undefined ca. 2 primary lung ca.
I Liver D612- B72.3+ Undefined ca. I met. colon ca.
Total 24
aSampled by CT-FNA; bNo. confirmed diagnoses/no. tested.
This clinical behaviour raises two main diagnostic prob-
lems in the management of colon-rectum carcinoma: (a) the
identification of the colonic origin of metastases in patients
bearing an occult primary tumour; (b) the correct diagnosis
of recurrence in patients previously treated for a colon car-
cinoma.
Although serial determinations of serum CEA have been
reported as an early sign of recurrence of colon carcinoma,
this has been shown to be correct only in 58% of the patients
(Eisman et al., 1982). In addition, in patients with a cryptic
primary tumour the measurement of CEA levels may be of
little diagnostic value. This is due to the low tumour
specificity of this marker.
Present radiological (Dixon et al., 1981; Gianola et al.,
1984; Waneck et al., 1984) and ultrastructural (Osamura et
al., 1985) methods to answer these questions still suffer from
gross inaccuracy due to their lack of tumour specificity, or
are often not performed on a routine basis.
Although the cytopathological analysis either of metastatic
effusions or of FNA of non-palpable lesions detected on
CT-scan represents a useful diagnostic tool for the staging
and monitoring of patients bearing a colon-rectum cancer, it
requires considerable experience and a correct morphological
diagnosis of tumour origin, which can be made only in the
clinical context of a known primary tumour (Ghosh et al.,
1983; Orell & Dowling 1983; Hilborne et al., 1985).
The application of immunocytochemical methods on
different cellular substrates (effusions, fine needle aspirates)
could be expected to contribute to an increase in the diagnos-
tic accuracy of the conventional cytopathology in these areas
by introducing both the specificity of an antigen-antibody
reaction and an objective interpretation of the results.
Attempts in this context have been only partially successful
because of the lack of highly tumour specific antibodies (To
et al., 1982; Ramaekers et al., 1984; Kyrkou et al., 1985;
Johnston et al., 1986). Ideal reagents in this context should
be capable of recognising a tumour associated antigen (TAA)
endowed with: (a) high colon cancer specificity; (b)
homogeneous expression unrelated to various degrees of
tumour differentiation; (c) homogenous expression in meta-
static foci independently from their anatomical distribution.
Because the high molecular weight TAA recently identified
by the murin MoAb D612 appears to fulfil most of these
requirements we have employed this antibody in
immunocytochemical assays aimed at evaluating whether this
reagent is capable of increasing the accuracy ofcytodiagnosis
of colon-rectum cancer. Because this differentiation antigen is
also expressed by about 20% of mucinous ovarian, lung,
breast and gastric primary carcinomas, in order to increase
the diagnostic accuracy of MoAb D612 this reagent has been
employed together with other MoAb which have already
been shown to possess a high diagnostic value (Mottolese et
al., 1988) when used in combination in detecting breast, lung
and ovarian tumours. Otherwise MoAb D612, when tested
on 60 effusions metastatic from breast, lung and serous
ovarian carcinomas, was negative in 95% of the instances,
thus demonstrating a restricted reactivity to primary and
metastatic colon-rectum carcinomas. Two clinical features of
colon-rectum cancer bearing patients should be recalled.
First, as reported by different authors, more than 30% of all
metastatic ovarian tumours are actually metastases from
colon-rectum carcinomas (Harcourt & Dennis, 1968; Mazur
et al., 1984) and unsuspected intestinal tumours are often
found in women presenting an ovarian mass initially diag-
nosed as a primary epithelial ovarian neoplasia (Morrow &
Enker, 1984; Lash & Hart, 1987). In these clinical cases
CT-guided FNA of ovarian tumours offers an accurate and
relatively atraumatic alternative to surgical biopsy in many
instances (Sevin & Nedji, 1983) avoiding time-delay and cost
of surgery and allowing an adequate treatment of the patient
immediately. However, FNA cytology of pelvic tumours is
frequently difficult and it is often impossible to establish
whether the specimens derive from a primary or metastatic
tumour only on the basis of the morphological picture (Linsk
& Franzen, 1983). Primary ovarian carcinomas, in some
instances, can display the same cytological appearance as a
metastatic adenocarcinoma. Furthermore, patients previously
treated for a colon-rectum tumour are known to be at high
risk to develop a second neoplasia of mammary, endometrial
and pulmonary origin (Cahan et al., 1974; Sugarbaker et al.,
1985). The results of the present study which employed
MoAb D612 on different cytological specimens have shown
that the addition of this reagent to a number of selected
MoAb may help to increase the accuracy of this diagnostic
panel of reagents by: (a) identifying the colonic origin of
recurrences and of metastases in patients with an occult
primary tumour; (b) detecting the presence of a second neo-
plasia in patients with a previous history other than colon
cancer; (c) providing a differential diagnosis between primary
ovarian tumour and ovarian metastases from a colon-rectum.
The addition to this diagnostic panel of MoAb recognising
mucinous ovarian tumours such as those described recently
by Sakakibara et al. (1988) may allow the differential diag-
nosis between metastatic mucinous colon carcinoma to the
ovary from primary mucinous ovarian tumours. Further-
more, the lack of reactivity of MoAb D612 with prostatic
cancer (Muraro et al., 1989), although not evaluated
immunocytochemically in the present study, is also likely to
allow a differential diagnosis between colon and prostate
tumours.
In conclusion, these findings clearly indicate that MoAb
D612 may help to improve the diagnosis of colon carcinoma
in different clinical situations as shown by the two clinical
cases reported, thus allowing the choice of adequate
therapeutic strategies of this neoplasia, which represents one
of the most common internal malignancies in both sexes.
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